405

Johnson & Johnson (JNJ-N)

ON STOCKCHASE SINCE Oct 2000

biotechnology/pharmaceutical

Johnson & Johnson
JNJ-N

153 watching

Join the Discussion

Expert Opinions
0 comments
Your Reaction

0 0 0 0 0

What the experts are saying about JNJ-N

Signal	Opinion	Expert
BUY	Johnson & Johnson(JNJ-N) January 10, 2019 Would the hiccup they had with the baby powder be a problem for the company and it is safe to step in? - Still own this company. They had it for a couple of years. The company said the product is safe and they said that the evidence is in their side. It is a triple A rated company. Their pharmaceutical division is doing very well. The dividend is very attractive and with the pullback it is good to step in. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	Would the hiccup they had with the baby powder be a problem for the company and it is safe to step in? - Still own this company. They had it for a couple of years. The company said the product is safe and they said that the evidence is in their side. It is a triple A rated company. Their pharmaceutical division is doing very well. The dividend is very attractive and with the pullback it is good to step in. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Christine Poole CEO & Mana, GlobeInvest Capital ... Price $129.710 Owned Yes

BUY on WEAKNESS	Johnson & Johnson(JNJ-N) December 20, 2018 One of the biggest companies in the world. Pharama and consumer products. They were hit with a multi-billion dollar law suit that their baby powder has chemicals in it rather than just talc. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	One of the biggest companies in the world. Pharama and consumer products. They were hit with a multi-billion dollar law suit that their baby powder has chemicals in it rather than just talc. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Norman Levine Managing D, Portfolio Management... Price $128.270 Owned Unknown
DON'T BUY	Johnson & Johnson(JNJ-N) December 19, 2018 It is suffering from asbestos in their talcum powder. This issue goes back four decades. The company is doing major damage control and he is not sure how it will end up. He would stay way. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	It is suffering from asbestos in their talcum powder. This issue goes back four decades. The company is doing major damage control and he is not sure how it will end up. He would stay way. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Gordon Reid President, GoodReid Investment ... Price $127.610 Owned No
BUY	Johnson & Johnson(JNJ-N) December 13, 2018 This is a portfolio anchor type of company. It is defensive and pays a great dividend for a US equity. If you want to make a bet on Pharma you would not use this one because there are two other businesses in there. These other two businesses give it some diversification. It is a good long term play. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	This is a portfolio anchor type of company. It is defensive and pays a great dividend for a US equity. If you want to make a bet on Pharma you would not use this one because there are two other businesses in there. These other two businesses give it some diversification. It is a good long term play. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Kash Pashootan CEO & Chie, First Avenue Investm... Price $147.840 Owned No
HOLD	Johnson & Johnson(JNJ-N) November 16, 2018 Worries about if markets do sell off. It’s had a great run up. It would have to get above levels it’s at. He’d buy because it’s still trending higher, but with the caveat to be careful with the DOW and S&P if they start to sell off. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	Worries about if markets do sell off. It’s had a great run up. It would have to get above levels it’s at. He’d buy because it’s still trending higher, but with the caveat to be careful with the DOW and S&P if they start to sell off. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Elliott Fishman Director o, Trading Services Gro... Price $145.990 Owned Unknown
COMMENT	Johnson & Johnson(JNJ-N) November 12, 2018 Avoided today's sell-off. Chart has a fantastic uptrend since 2014, though it's been oversold and overbought in periods. Current price is just below its January peak. This year it has a cup and handle pattern, which is good. It's not testing its January high. JNJ come be a defensive play, or it could go sideways or even drift down. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	Avoided today's sell-off. Chart has a fantastic uptrend since 2014, though it's been oversold and overbought in periods. Current price is just below its January peak. This year it has a cup and handle pattern, which is good. It's not testing its January high. JNJ come be a defensive play, or it could go sideways or even drift down. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Hap (Robert) Sn Chief Port, Castlemoore Inc.... Price $145.620 Owned Unknown
HOLD	Johnson & Johnson(JNJ-N) November 9, 2018 He is overweight in both pharmaceuticals and biotechnology. It is nearing a 52 week high. They have continuously raised the dividend. It is a defensive name. There are other names in this sector that he prefers. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	He is overweight in both pharmaceuticals and biotechnology. It is nearing a 52 week high. They have continuously raised the dividend. It is a defensive name. There are other names in this sector that he prefers. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Rob Tetrault Portfolio , Tetrault Wealth Advi... Price $145.340 Owned No
WEAK BUY	Johnson & Johnson(JNJ-N) October 23, 2018 Healthcare names are defensive and a portfolio needs them, but JNJ is flat YTD. If your portfolio is light in defensive names, then consider this. Buy according to your overall portfolio composition. Consumer and medical product divisions have modest growth. Pharma is its big driver of growth. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	Healthcare names are defensive and a portfolio needs them, but JNJ is flat YTD. If your portfolio is light in defensive names, then consider this. Buy according to your overall portfolio composition. Consumer and medical product divisions have modest growth. Pharma is its big driver of growth. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Kash Pashootan CEO & Chie, First Avenue Investm... Price $138.930 Owned No
BUY	Johnson & Johnson(JNJ-N) October 11, 2018 Great company. Pharma, medical devices and consumer are their 3 divisions, which makes them unique--that diversification serves them well, unlike phrama companies depend solely on their pharma division. Has raised dividend for 54 years. Well run. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	Great company. Pharma, medical devices and consumer are their 3 divisions, which makes them unique--that diversification serves them well, unlike phrama companies depend solely on their pharma division. Has raised dividend for 54 years. Well run. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Paul Harris, CF Portfolio , Avenue Investment Ma... Price $133.840 Owned Yes
PAST TOP PICK	Johnson & Johnson(JNJ-N) October 10, 2018 (Past Top Pick Oct.10, 2017,Up 10%) Their pharma is doing quite well. All health companies are facing patent losses, but J&J is positioned to weather this, because they're launching 10 new drugs in the next 18 months. In this defensive environment, this should hold up well. Have been increasing their dividend for 56 years, now paying a 2.5% yield. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	(Past Top Pick Oct.10, 2017,Up 10%) Their pharma is doing quite well. All health companies are facing patent losses, but J&J is positioned to weather this, because they're launching 10 new drugs in the next 18 months. In this defensive environment, this should hold up well. Have been increasing their dividend for 56 years, now paying a 2.5% yield. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Christine Poole CEO & Mana, GlobeInvest Capital ... Price $137.730 Owned Yes
BUY	Johnson & Johnson(JNJ-N) August 30, 2018 He loves it. The judgment against them is not significant. He has a model price of $160.81, a 20% upside. It is in the top 100 of the S&P 500 - it is US and priced in US Dollars – all the things he loves. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	He loves it. The judgment against them is not significant. He has a model price of $160.81, a 20% upside. It is in the top 100 of the S&P 500 - it is US and priced in US Dollars – all the things he loves. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Brian Acker, CA Chief Exec, Acker Finley Inc.... Price $134.950 Owned Unknown
COMMENT	Johnson & Johnson(JNJ-N) August 27, 2018 Trading at a high mulitple, but has tranditioned well from the consumer space to heathcare. It's well-positioned for international growth, but the rising US dollar is a headwind. Market performance is the best you'll get from J&J. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	Trading at a high mulitple, but has tranditioned well from the consumer space to heathcare. It's well-positioned for international growth, but the rising US dollar is a headwind. Market performance is the best you'll get from J&J. biotechnology/pharmaceutical 0 0 0 0 0 0 comments John Zechner Chairman, J. Zechner & Assoc... Price $134.920 Owned Unknown
TOP PICK	Johnson & Johnson(JNJ-N) July 10, 2018 Their stock has done nothing this year, partially because of pricing pressure from Donald Trump. She thinks their pharma division is doing well, with lots of new products and a good pipeline. They have identified 10 drugs that have a $1 billion potential. This company spends 13% of revenues on R&D, which shows a serious level of investment in the future. They have also made some acquisitions to go into new areas. They have increased their dividend consistently for over 50 years. (Analysts’ price target is $143.29) biotechnology/pharmaceutical 0 0 0 0 0 0 comments	Their stock has done nothing this year, partially because of pricing pressure from Donald Trump. She thinks their pharma division is doing well, with lots of new products and a good pipeline. They have identified 10 drugs that have a $1 billion potential. This company spends 13% of revenues on R&D, which shows a serious level of investment in the future. They have also made some acquisitions to go into new areas. They have increased their dividend consistently for over 50 years. (Analysts’ price target is $143.29) biotechnology/pharmaceutical 0 0 0 0 0 0 comments Christine Poole CEO & Mana, GlobeInvest Capital ... Price $127.380 Owned Yes
BUY	Johnson & Johnson(JNJ-N) June 7, 2018 It is a very well run company. Pharma, medical supply and personal goods businesses. The pharma business is doing well. They have a number of drugs. Brands are not as valued by millennials as by their predecessors. This is the struggle that JNJ-N is having. They have a strong balance sheet and a nice dividend. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	It is a very well run company. Pharma, medical supply and personal goods businesses. The pharma business is doing well. They have a number of drugs. Brands are not as valued by millennials as by their predecessors. This is the struggle that JNJ-N is having. They have a strong balance sheet and a nice dividend. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Gordon Reid President, GoodReid Investment ... Price $123.330 Owned Unknown
PAST TOP PICK	Johnson & Johnson(JNJ-N) May 8, 2018 (Past Top Pick on May 16, 2017, Down 1.5%) Their pharma side and newly released drugs are doing very well which offsets their drugs that are going generic. They have a solid pipeline of 10 new drugs over the next few years, each drug expected to make $1-billion. They invest in R&D and buy companies occasionally, including one last year. Yield under 3%. biotechnology/pharmaceutical 0 0 0 0 0 0 comments	(Past Top Pick on May 16, 2017, Down 1.5%) Their pharma side and newly released drugs are doing very well which offsets their drugs that are going generic. They have a solid pipeline of 10 new drugs over the next few years, each drug expected to make $1-billion. They invest in R&D and buy companies occasionally, including one last year. Yield under 3%. biotechnology/pharmaceutical 0 0 0 0 0 0 comments Christine Poole CEO & Mana, GlobeInvest Capital ... Price $122.610 Owned Yes

Stockchase, in its reporting on what has been discussed by indviduals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

© Stockchase Inc. & Wealthica Financial Technology Inc.